Entos Pharmaceuticals Inc. (Entos) is a biotech business that creates genetic therapies using its non-viral, redosable Fusogenix PLV delivery technology. CureDuchenne Ventures announced an initial $1 million investment in Entos. In order to cure Duchenne muscular dystrophy (DMD), Entos will use this financing to develop a muscle-targeting therapy that delivers full-length dystrophin.
CureDuchenne Ventures Invests in Entos Pharmaceuticals
“We are very excited by the potential of Entos Pharmaceuticals’ technology and look forward to collaborating with Entos in pursuit of a gene therapy that overcomes the limitations of current AAV-based approaches—one that would not exclude individuals with pre-existing immunity, allow for redosing, and, crucially, deliver full-length dystrophin to all of the necessary muscle tissues,” said Debra Miller, founder and CEO of CureDuchenne. – Fusogenix PLV –
“CureDuchenne has long been a leader in funding innovative therapeutic approaches, and this investment underscores our continued use of venture philanthropy to catalyze progress towards transformative treatments for Duchenne. We extend our heartfelt gratitude to our donors and the Duchenne community—your support has made this investment possible and continues to drive progress toward a cure.”
What is Fusogenix PLV
The Fusogenix PLV delivery platform is formulated with our proprietary fusogenic FAST proteins to drive fusion and intracellular delivery of therapeutic nucleic acid payloads to cells and tissues throughout the body – to make these much needed therapies a reality.
“The Fusogenix PLV platform enables the safe, effective, and redosable delivery of full-length functional genes, like dystrophin, to muscle cells throughout the body. Given that Fusogenix PLV-based treatments can be given more than once, if needed, this could be a real game-changer,” said John Lewis, CEO of Entos Pharmaceuticals. “We’re hopeful this approach will make a real difference for people with Duchenne muscular dystrophy and their families.”
